HSP110-IN-1 是一种 HSP110 抑制剂,可与 HSP110 结合并抑制 STAT3 活性,下调下游基因 VEGF、MMP7 和 MMP9 的表达,消除 IL-6 诱导的上皮间质转化并抑制结肠直肠癌细胞增殖,还能通过诱导促炎表型重塑肿瘤微环境、调控巨噬细胞、诱导 PD-L1 表达并增强抗 PD-L1 抗体介导的肿瘤消退,可用于结直肠癌的相关研究。
产品编号: MS-C80746 CAS No.: 2991567-27-0 分子式: C29H32N4O5 分子量: 516.59
MolStrong 的所有产品仅用作科学研究或药证申报,我们不为任何个人用途提供产品和服务
规格 价格 是否有货 数量 购物车
50mg
询价
询价
100mg
询价
询价
250mg
询价
询价

产品描述

HSP110-IN-1 是一种 HSP110 抑制剂,可与 HSP110 结合并抑制 STAT3 活性,下调下游基因 VEGF、MMP7 和 MMP9 的表达,消除 IL-6 诱导的上皮间质转化并抑制结肠直肠癌细胞增殖,还能通过诱导促炎表型重塑肿瘤微环境、调控巨噬细胞、诱导 PD-L1 表达并增强抗 PD-L1 抗体介导的肿瘤消退,可用于结直肠癌的相关研究。

生物实验数据

生物活性 HSP110-IN-1 is an HSP110 inhibitor that binds to HSP110 and inhibits STAT3 activity, downregulates the expression of downstream genes VEGF, MMP7, and MMP9, abolishes IL-6-induced epithelial-mesenchymal transition and suppresses colorectal cancer cell proliferation, and also remodels the tumor microenvironment by inducing a pro-inflammatory phenotype, modulates macrophages, induces PD-L1 expression, and enhances anti-PD-L1 antibody-mediated tumor regression, making it useful for research related to colorectal cancer.
IC50 & Target

HSP110

 

STAT3

 

MMP-9

 

MMP-7

 

体外研究
(In Vitro)

HSP110-IN-1 (Compound 7) (75 μM; 72 h) 可强效抑制 HCT116 和 SW480 人结直肠癌细胞的活力,抑制率分别为 72.9% 和 81.3%。
HSP110-IN-1 (0-500 μM; 48 h) 以剂量依赖方式抑制 HCT116 和 SW480 人结直肠癌细胞的活力,其 IC50 值分别为 11.59 μM 和 6.05 μM。
HSP110-IN-1 (0-10 μM; 24 h) 可剂量依赖性地抑制人结直肠癌细胞 HCT116 和 SW480 中 STAT3 的磷酸化,且不影响总 STAT3 或 HSP110 的水平。
HSP110-IN-1 (5-10 μM; 24 h) 可下调 HCT116 和 SW480 人结直肠癌细胞中 STAT3 靶基因 MMP7、MMP9 及 VEGF 的表达。
HSP110-IN-1 (5-10 μM; 48 h) 可抑制 IL-6 诱导的人结直肠癌细胞 HCT116 和 SW480 的迁移。
HSP110-IN-1 (5-10 μM; 24 h) 可抑制 IL-6 诱导的人结直肠癌细胞 HCT116 和 SW480 的侵袭。
HSP110-IN-1 (5-10 μM; 24 h) 可减弱 IL-6 诱导的人结直肠癌细胞 HCT116 和 SW480 发生上皮间质转化。
HSP110-IN-1 (Compound c7) (40 μM; 96 h) 可抑制与 PBMC 共培养的人 HCT 116 和 HT-29 结直肠癌 3D 球体的生长。
HSP110-IN-1 (40 μM; 48 h) 可将人源 M2 样巨噬细胞极化为促炎型 M1 样表型,并增强人源 M1 样巨噬细胞中促炎标志物的表达,同时上调这两种巨噬细胞亚群中的 PD-L1 表达。
HSP110-IN-1 (40 μM; 48 h) 处理 M2 样巨噬细胞可间接促进共培养的自体人 CD8+ T 淋巴细胞的增殖及 IFN-γ 产生,抗 PD-1 联合处理可增强该效应,但该化合物对 CD8+ T 细胞增殖无直接作用。
HSP110-IN-1 (40 μM; 48 h) 处理人源 M1 样或 M2 样巨噬细胞后,可使这些巨噬细胞抑制共培养的 HT-29 结直肠癌 3D 球状体的生长;当存在自体活化 T 淋巴细胞时,该抑制作用会增强。

Cell Viability Assay

Cell Line: human colorectal cancer HCT116 and SW480 cells
Concentration: 75 μM
Incubation Time: 72 h
Result: Produced the highest inhibition rate against HCT116 and SW480 cells among tested compounds, with an inhibition rate of 72.9% in HCT116 cells and 81.3% in SW480 cells.

Western Blot Analysis

Cell Line: human colorectal cancer HCT116 and SW480 cells
Concentration: 0, 1.25, 2.5, 5 and 10 μM
Incubation Time: 24 h
Result: Reduced phosphorylated STAT3 levels in a dose-dependent manner in both cell lines, without altering total STAT3 or HSP110 expression.
Inhibited STAT3 phosphorylation more significantly than the reference compound 1 at 5 and 10 μM.

Real Time qPCR

Cell Line: human colorectal cancer HCT116 and SW480 cells
Concentration: 5 and 10 μM
Incubation Time: 24 h
Result: Substantially downregulated the expression of STAT3 downstream target genes MMP7, MMP9, and VEGF in both cell lines.
Exhibited more significant inhibitory effect than the reference compound 1 at 10 μM.

Cell Migration Assay

Cell Line: IL-6-stimulated human colorectal cancer HCT116 and SW480 cells
Concentration: 5 and 10 μM (with 6.25 ng/mL IL-6 stimulation)
Incubation Time: 48 h
Result: Suppressed IL-6-induced cell migration in a dose-dependent manner.
Exhibited more potent inhibitory effects on wound closure than the reference compound 1 at 10 μM.

Cell Invasion Assay

Cell Line: IL-6-stimulated human colorectal cancer HCT116 and SW480 cells
Concentration: 5 and 10 μM (with 6.25 ng/mL IL-6 stimulation)
Incubation Time: 24 h
Result: Suppressed IL-6-induced cell invasion in a dose-dependent manner.
Exhibited more potent inhibitory effects on cell invasion than the reference compound 1 at 10 μM.

Western Blot Analysis

Cell Line: IL-6-stimulated human colorectal cancer HCT116 and SW480 cells
Concentration: 5 and 10 μM (with 6.25 ng/mL IL-6 stimulation)
Incubation Time: 24 h
Result: Increased the expression of epithelial marker E-cadherin and decreased the expression of mesenchymal markers N-cadherin and Snail in IL-6-stimulated cells.
Produced more significant reversal of EMT markers than the reference compound 1 at 5 and 10 μM.
体内研究
(In Vivo)

HSP110-IN-1 (Compound 7) (5 mg/kg;腹腔注射;每 3 天 1 次;持续 30 天) 在 HCT116 异种移植小鼠体内发挥显著的体内肿瘤生长抑制作用。
HSP110-IN-1 (Compound c7) (5 mg/kg;腹腔注射;每周 3 次;持续 21 天) 可使 BALB/c 小鼠的 CT26 结直肠肿瘤生长抑制 75%-80%,将肿瘤微环境重塑为促炎状态,并上调多种细胞类型中的 PD-L1 表达,且在测试剂量下未检测到毒性。
HSP110-IN-1 (5 mg/kg;腹腔注射;每周 3 次;持续 21 天) 可增强抗 PD-L1 疗法在 BALB/c 小鼠抗 PD-L1 耐药 CT26 结直肠肿瘤中的疗效,促进肿瘤消退、重塑肿瘤微环境并促进功能性 CD8+肿瘤浸润淋巴细胞的生成。
HSP110-IN-1 (5 mg/kg;腹腔注射;每周 3 次;持续 21 天) 可增强抗 PD-L1 疗法在 C57BL/6 小鼠抗 PD-L1 敏感型 MC38 结直肠癌模型中的疗效,促使肿瘤消退效果更优并重塑肿瘤微环境。

Animal Model: BALB/c nude mice (male, 4-6 weeks old, 18-23 g, HCT116 human colorectal cancer cell xenograft)
Dosage: 5 mg/kg
Administration: i.p.; every three days; 30 days
Result: Reduced tumor volumes and weights significantly.
Reduced expression of STAT3 downstream genes VEGF and MMP9 significantly in tumor tissues.
Increased expression of tumor suppressor protein p53 significantly in tumor tissues.
Caused no significant changes in body weight.
Animal Model: BALB/c (8-10-week-old female; subcutaneous injection of 5×105 CT26 wild-type cells)
Dosage: 5 mg/kg
Administration: i.p.; three times weekly; 21 days
Result: Induced a 75-80% reduction in tumor growth compared to vehicle controls.
Increased tumor cell apoptosis and reduced phosphorylated STAT3 levels in tumor tissue compared to vehicle and first-generation inhibitor C33.
Reduced the expression of pro-tumoral M2-like tumor-associated macrophage marker CD206 without affecting M1-like marker CD80.
Increased PD-L1 expression in tumor-associated macrophages, tumor cells, myeloid-derived suppressor cells, and dendritic cells.
No toxicity detected via intestinal crypt apoptosis staining or body weight loss.\nSignificantly reduced tumor growth compared to vehicle.
When combined with anti-PD-L1, induced greater tumor regression than either monotherapy, including in the anti-PD-L1-resistant CT26 model.
Decreased CD206 expression in tumor-associated macrophages when used alone or in combination with anti-PD-L1.
Increased PD-L1 expression in tumor cells and M2-like macrophages, which was reduced by co-administration of anti-PD-L1.
Increased the percentage of CD8+ tumor-infiltrating lymphocytes co-expressing PD-1 and TIM-3 or PD-1 and LAG-3, which exhibited enhanced effector function (higher expression of granzyme B, IFN-γ, and IL-2) compared to monotherapies or vehicle.
Animal Model: C57BL/6 (8-10-week-old female; subcutaneous injection of 5×105 MC38 cells)
Dosage: 5 mg/kg
Administration: i.p.; three times weekly; 21 days
Result: Significantly reduced tumor growth compared to vehicle.
When combined with anti-PD-L1, induced greater tumor regression than either monotherapy in the anti-PD-L1-sensitive MC38 model.
Decreased CD206 expression in tumor-associated macrophages when used alone or in combination with anti-PD-L1.
Increased PD-L1 expression in tumor cells and M2-like macrophages, which was reduced by co-administration of anti-PD-L1.

化学信息

分子量 516.59
分子式 C29H32N4O5
CAS No. 2991567-27-0

储存&溶解度

储存方式

Please store the product under the recommended conditions in the Certificate of Analysis.

运输条件 Room temperature in continental US; may vary elsewhere.

计算器

质量 (mg) = 浓度 (mM) x 体积 (mL) x 分子摩尔量 (g/mol)
Mass (g) = Concentration (mol/L) × Volume (L) × Molecular Weight (g/mol)
起始浓度(M)× 起始体积(L)= 最终浓度(M)× 最终体积(L)
Concentration (start) × Volume (start) = Concentration (final) × Volume (final)
This equation is commonly abbreviated as: C1V1 = C2V2
溶液体积 = 质量 ÷ 配液浓度
Volume (to add to vial) = Mass (in vial) ÷ Desired Reconstitution Concentration
÷
分子量计算器
Enter the chemical formula of the compound to calculate its molar mass and elemental composition
g/mol

体内实验配液计算器

动物实验计算换算器

请在以下方框中输入您的动物实验信息后点击计算,可以得到母液配置方法和体内配方的制备方法:

比如您的给药剂量是10 mg/kg,每只动物体重20 g,给药体积100 μL, 一共给药动物10只,您使用的配方为 10% DMSO + 40% PEG300 + 5% Tween 80 + 45% Saline / PBS / ddH2O, 那么您的工作液浓度为2 mg/mL。

母液配置方法:2 mg 药物溶于 100 μL DMSO ( 母液浓度为 20 mg/mL ), 如您需要配置的浓度超过该产品的溶解度,请先与我们联系。

体内配方的制备方法: 取 100 μL DMSO 母液, 添加 400 μL PEG300 混匀澄清, 再加 50 μL Tween 80, 混匀澄清, 再加 450 μL Saline / PBS / ddH2O 混匀澄清

以上为“体内实验配液计算器”的使用方法举例,并不是具体某个化合物的推荐配制方式,请根据您的实验动物和给药方式选择适当的溶解方案。

方案所需的各类助溶剂如: DMSO, PEG300, PEG400, Tween 80, SBE-β-CD, 玉米油等, 均可在MolStrong网站点击购买。

第一步:请输入基本实验信息(考虑到实验过程中的损耗,建议多配一只动物的药量)
第二步:请输入动物体内配方组成(配方适用于不溶于水的药物;不同批次药物配方比例不同,请联系客服为您提供正确的澄清溶液配方)
+
+
+

计算结果:

工作液浓度: mg/ml;

DMSO母液配制方法: mg 药物溶于 μL DMSO溶液(母液浓度 mg/mL,

体内配方配制方法:取 μL DMSO母液,加入 μL PEG300,混匀澄清后加入μL Tween 80,混匀澄清后加入 μL Saline/PBS/ddH2O,混匀澄清。

1. 首先保证母液是澄清的;
           2. 一定要按照顺序依次将溶剂加入,进行下一步操作之前必须保证上一步操作得到的是澄清的溶液,可采用涡旋、超声或水浴加热等物理方法助溶。

开始您的科研之旅

20,0000+ 种高纯度分子化合物,专业靶点数据库,全程技术支持
让每一个实验数据都有坚实的分子基础